What to know about the new GLP-1 pills now on sale

Novo Nordisk's Wegovy and Lilly's Foundayo, oral GLP-1 weight loss pills, are now available in Australia. Experts anticipate increased demand but caution about long-term effects and misuse. Prices range from $250 to $395 monthly, comparable to injectable versions. Availability varies by pharmacy.

Original reporting
Published Nov 19, 2026, 10:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 20, 2026, 7:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
What to know about the new GLP-1 pills now on sale — source image
Decision brief

The 30-second read

$NVOBullishHigh
01

Why it matters

The approvals create a new revenue stream for both companies and could shift market dynamics toward oral obesity treatments.

02

Market read

Regulatory approval of oral GLP‑1 drugs expands market opportunities for Novo Nordisk and Eli Lilly, potentially boosting their stock performance and influencing the broader weight‑loss drug sector.

03

What to watch

Australian reimbursement policies and consumer price sensitivity may affect uptake.

Relevance 7/10Novelty 9/10Timing: available starting Friday

Background

Australia approved the first oral GLP‑1 pills for weight loss, with Novo Nordisk's Wegovy and Eli Lilly's Foundayo entering pharmacies. Experts note potential demand surge but raise concerns about long‑term safety and pricing.

Company-level read

Ticker impact

$NVOBullishHigh confidence
Context

Novo Nordisk received TGA approval for its oral Wegovy GLP-1 pill, launching in Australian pharmacies this Friday.

Expected impact

likely upside as investors price in additional revenue from oral GLP-1 sales

Evidence & confidence

First approval of an oral GLP-1 expands market reach and adds revenue potential, prompting positive market reaction.

$LLYBullishHigh confidence
Context

Eli Lilly announced its oral GLP-1 pill Foundayo will be available in Australia after TGA approval, entering the market in the coming days.

Expected impact

potential upside as the market anticipates new revenue from Australian sales

Evidence & confidence

Entry into the Australian oral GLP-1 market adds growth opportunity, likely supporting the stock.

Market effects

Weight‑loss drug sector may see increased demand for oral GLP‑1 therapies.

Australian pharma market gains a new oral obesity treatment, potentially boosting local sales.

Global GLP‑1 market could grow as oral options expand, influencing US‑listed pharma stocks.

Counterpoint

Overprescription risks and high pricing could limit adoption and dampen sales expectations.

Key entities

  • Novo Nordisk

    Pharmaceutical company launching oral Wegovy GLP‑1 pill in Australia.

  • Eli Lilly

    Pharmaceutical company launching oral Foundayo GLP‑1 pill in Australia.

  • Therapeutic Goods Administration (TGA)

    Australian regulator that approved the oral GLP‑1 medications.

Related articles

$NVOMed

Could weight-loss drugs become widely used by children as young as six?

Novo Nordisk's Wegovy (semaglutide) showed promise in reducing BMI in children aged 6-12 in a 68-week trial, with 81.5% of participants seeing improvements. Experts note childhood obesity is a growing public health concern, with long-term risks including Type 2 diabetes and cardiovascular disease. Wegovy is already approved for adolescents, and researchers suggest early treatment may prevent co-morbidities. Concerns exist about long-term side effects and over-reliance on weight-loss drugs.

$NVOHigh

Novo's Sogroya® receives FDA approval as the first and only once-weekly, long-acting growth hormone for children with Turner Syndrome (TS)

Novo Nordisk's Sogroya® received FDA approval as the first once-weekly growth hormone treatment for children with Turner Syndrome. The approval is based on the REAL8 trial, which showed positive growth and safety outcomes. Sogroya® offers a simpler treatment routine with 313 injection-free days per year, potentially benefiting patients and caregivers. The drug is also approved for other growth disorders and adult growth hormone deficiency.

$NVOLow

GLP-1 vision warning: Could demand be affected?

The FDA requires GLP-1 drugs to carry warnings about a potential increased risk of NAION, a condition that can cause vision loss. Analysis showed 6.4 cases per 100,000 person-years among users, though no causal link has been established. Experts believe the warnings will have limited impact on demand. Novo Nordisk and Eli Lilly, manufacturers of GLP-1 drugs, responded to the FDA's requirements, emphasizing patient safety and the lack of specific findings related to their medicines.

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$LLYMed

ACR: Retatrutide Beneficial in Adults With Painful Knee OA, Obesity

A study published in the New England Journal of Medicine found that retatrutide, developed by Eli Lilly, significantly reduced knee pain and body weight in adults with painful knee osteoarthritis and obesity compared to placebo. The trials showed mean WOMAC pain score reductions of -3.96 and -3.74 for 9mg and 12mg doses, respectively, versus -2.12 for placebo, and weight reductions of -20.0% and -23.7% versus -4.6%. Serious adverse events were more common with retatrutide.